Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Panagiotis A. Konstantinopoulos, Sampsa Hautaniemi et al.|Nature Communications|2020Cited by 342
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination ImmunotherapySonia Iyer, Robert A. Weinberg, Shuang Zhang et al.|Cancer Discovery|2020Cited by 138
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancerInga-Maria Launonen, Anniina Färkkilä, Nuppu Lyytikäinen et al.|Nature Communications|2022Cited by 121
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancerInga-Maria Launonen, Anniina Färkkilä|Cancer Cell|2024Cited by 56
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Panagiotis A. Konstantinopoulos, D. Gulhan et al.|Nature Communications|2020Cited by 13